White House Orders Psychedelic Expansion, $50M Allocation, FDA Fast-Track Amid Marijuana Rescheduling Pressure
The Trump administration has initiated a significant reversal of Republican drug policy orthodoxy, signing an executive order to accelerate psychedelic treatments for mental health conditions while simultaneously pressuring the Drug Enforcement Administration to downgrade marijuana's controlled substance classification.
The executive order directs $50 million toward psychedelic research and instructs the Food and Drug Administration to expedite approval reviews for certain psychedelics. At the signing event, which included podcaster Joe Rogan and a former Navy SEAL, President Trump lightheartedly remarked: "Can I have some, please?" The administration has simultaneously announced the downgrading of medical marijuana from the highest tier of controlled substances, with recreational marijuana rescheduling now under active pursuit. Officials have emphasized that this leniency applies selectively—hardline, militaristic enforcement remains in place for fentanyl and synthetic opioids.
The moves mark a departure from decades of Republican opposition to loosening drug restrictions, signaling a potential realignment of the party's stance on controlled substances. The psychedelic sector, particularly companies developing psilocybin and MDMA-assisted therapies, faces immediate regulatory scrutiny as FDA review timelines compress. DEA rescheduling of marijuana could reshape state-federal legal conflicts, affect cannabis industry banking access, and alter criminal enforcement priorities. Mental health advocacy groups have expressed cautious optimism, while traditional drug policy hawks within the Republican coalition face pressure to respond. The dual-track approach—aggressive enforcement on some substances, permissive expansion on others—suggests an evolving and potentially contradictory framework that stakeholders across the pharmaceutical, law enforcement, and public health sectors will need to monitor closely.